Viatris
| File:Viatris logo.jpg | |
| Company type | Public |
|---|---|
| ISIN | US92556V1061 |
| Industry | Pharmaceuticals |
| Predecessors | |
| Founded | November 16, 2020 |
| Headquarters | , United States of America |
Area served | Worldwide |
Key people | Robert J. Coury (Executive Chairman)
Michael Goettler (CEO) |
| Products | Branded and generic pharmaceuticals and active pharmaceutical ingredients |
| Website | www |
Viatris Inc. is an American-based global healthcare company formed through the merger of Mylan and Upjohn on November 16, 2020.[1]
The name comes from the Latin words via, meaning path, and tris, which means three, referring to the path to three main objectives the company set.[2][3]
At the time of the combination, Michael Goettler became CEO of the new company.[1][4][5][6] Following the combination, the company began trading on the NASDAQ using the ticker symbol VTRS.[1]
The company produces and sells different types of medicines: brands (like Viagra, Xanax, Lipitor),[7][8] generics, including branded and complex generics, biosimilars, and over-the-counter (OTC) drugs and active pharmaceutical ingredients.[9] They belong to a wide range of therapeutic areas, such as cardiovascular, infectious disease, oncology, immunology, CNS and anesthesia, women's healthcare, diabetes and metabolism, gastroenterology, respiratory and allergy, and dermatology.[10]
History
The following is an illustration of the company's major mergers and acquisitions and historical predecessors:
- Viatris
- Mylan (Founded 1961, merged with Upjohn, 2020)
- Somerset Pharmaceuticals (Acq 1989)
- Dow B. Hickam (Acq 1991)
- Bertek Inc (Acq 1993)
- UDL Laboratories (Acq 1996)
- Penederm Inc (Acq 1998)
- Matrix Laboratories (Acq 2007)
- Merck KGaA (Generics div.) (Acq 2007)
- Bioniche Pharma Holdings (Acq 2010)
- Pfizer Respiratory Delivery Platform (Acq 2011)
- Agila Specialties (Acq 2013)
- Abbott Laboratories (Generics div.) (Acq 2014)
- Famy Care (Acq 2014)
- Meda (Acq 2016)
- Renaissance Acquisition Holdings (Dermatology div.) (Acq 2016)
- Upjohn (Divested from Pfizer & merged with Mylan, 2020)
- Mylan (Founded 1961, merged with Upjohn, 2020)
References
- ^ a b c Gough, Paul J. (16 November 2020). "After nearly 60 years, Mylan makes way for Viatris". Pittsburgh Business Times. Retrieved 16 November 2020.
- ^ "Viatris picked as new name for a merged Mylan/Upjohn". Pittsburgh Post-Gazette. Retrieved 2021-01-04.
- ^ "Pfizer's Upjohn and Mylan will become Viatris. Wait, haven't we heard that name before?". FiercePharma. Retrieved 2021-01-04.
- ^ Mamula, Kris B. (29 July 2019). "Mylan merger with Pfizer's Upjohn unit to form new company with $20 billion in revenues". Pittsburgh Post-Gazette. Retrieved 16 November 2020.
- ^ Sabatini, Patricia (12 November 2019). "Viatris picked as new name for a merged Mylan/Upjohn". Pittsburgh Post-Gazette. Retrieved 16 November 2020.
- ^ "Our Leaders". www.viatris.com. Retrieved 2021-01-04.
- ^ "Products". www.viatris.com. Retrieved 2021-01-04.
- ^ "Mylan merger with Pfizer's Upjohn unit to form new company with $20 billion in revenues". Pittsburgh Post-Gazette. Retrieved 2021-01-04.
- ^ "Our Story". www.viatris.com. Retrieved 2021-01-04.
- ^ "Therapeutic Areas". www.viatris.com. Retrieved 2021-01-04.
External links
- Official website
- Business data for Viatris:
| Authority control databases: National |
|---|
